Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

Federico V Grossi, MDPhD, Pauline Bedwell, Pascal Deschatelets, PhD, Lil Edis, PhD, Cedric G Francois, MDPhD, Patrick J Johnson, PhD, Helen J Richardson, Lisa Tan, Carolina A Vega, Jason Lickliter, MBBS,PhD

Blood (2016) 128 (22): 1251.

https://doi.org/10.1182/blood.V128.22.1251.1251

Published: 2016

Journal Articles

ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)

Sarah J. Richardson, Christine Matthews, Mark A. Catherwood, H. Denis Alexander, B. Sean Carey, Joanna Farrugia, Anne Gardiner, Sarah Mould, David Oscier, J. Adrian Copplestone, Archibald G. Prentice

Blood (2006) 107 (9): 3584–3592.

https://doi.org/10.1182/blood-2005-04-1718

Published: 2006

Journal Articles

Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail

MA Ghetie, K Tucker, J Richardson, JW Uhr, ES Vitetta

Blood (1994) 84 (3): 702–707.

https://doi.org/10.1182/blood.V84.3.702.702

Published: 1994

Journal Articles

A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy

PL Amlot, MJ Stone, D Cunningham, J Fay, J Newman, R Collins, R May, M McCarthy, J Richardson, V Ghetie

Blood (1993) 82 (9): 2624–2633.

https://doi.org/10.1182/blood.V82.9.2624.2624

Published: 1993

Journal Articles

The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin

MA Ghetie, K Tucker, J Richardson, JW Uhr, ES Vitetta

Blood (1992) 80 (9): 2315–2320.

https://doi.org/10.1182/blood.V80.9.2315.2315

Published: 1992

NARROW

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)

Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail

A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy

The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin

Email alerts

ASH Publications

American Society of Hematology

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)

Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail

A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy

The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only